64. Maisch, B., Bauer, E., Cirsi, M., Kochsiek, K. Cytolytic cross-reactive antibodies directed against the cardiac membrane and viral proteins in coxsackievirus B3 and B4 myocarditis. Characterization and pathogenetic relevance. Circulation 1993.
65. Jin O, Sole MJ, Butany JW, et al:Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction. Circulation. 1990, 82:8–16.
66. Moore, T. L. 2000. Parvovirus-associated arthritis. Curr. Opin. Rheumatol. 12:289-294.
67. Dingli, D., D. H. Pfizenmaier, E. Arromdee, P. et al. 2000. Severe digital arterial occlusive disease and acute parvovirus B19 infection. Lancet 356:312-314.
68.Hillingso, J. G., I. P. Jensen, and L. Tom-Petersen. 1998. Parvovirus B19 and acute hepatitis in adults. Lancet 351:955-956.
69. Crane, J. 2002. Parvovirus B19 infection in pregnancy. J. Obstet. Gynaecol. Can. 24:727-743.
70. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975; 1:72.
71. Virus taxonomy update. The International Committee on Taxonomy of Viruses. Arch Virol 1993; 133:491.
72. Kaufmann, B. The structure of human parvovirus B19 / B. Kaufmann, A. A. Simpson, M. G. Rossmann // Proc. Natl. Acad. Sci. U. S. A. –2004. –V. 101. –P. 11628–11633.
73. Norja, P. Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue / P. Norja [et al.] // Proc. Natl. Acad. Sci. U. S. A. –2006. –V. 103. –P. 7450–745310–11].
74. Servant A, Laperche S, Lallemand F, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002; 76:9124.
75. Norja P, Eis-Hübinger AM, Söderlund-Venermo M, et al. Rapid sequence change and geographical spread of human parvovirus B19: comparison of B19 virus evolution in acute and persistent infections. J Virol 2008; 82:6427.
76. Hübschen, J. M. Phylogenetic analysis of human parvovirus B19 sequences from eleven different countries confirms the predominance of genotype 1 and suggests the spread of genotype 3b / J. M. Hübschen [et al.] // J. Clin. Microbiol. – 2009. –V. 47. –P. 3735–3738.
77. Okochi, K. Nakatani antigen and human parvovirus (B19) / K. Okochi [et al.] // Lancet. – 1984. –V. 1. –P. 160–161.
78. Anderson, M. J. Experimental parvoviral infection in humans / M. J. Anderson [et al.] // J. Infect. Dis. – 1985. –V. 152. – P. 257–265.
79. Courouce, A. M. Human parvovirus infections in France /A. M. Courouce [et al.] // Lancet. – 1984. –V. 1. –P.160.].
80. Parsyan A, Szmaragd C, Allain JP, Candotti D. Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes. J Gen Virol 2007; 88:428
81. Kühl, U., Lassner, D., Pauschinger, M., Gross, U. M., Seeberg, B., Noutsias, M., Poller, W., Schultheiss, H. P. (2008). Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol. 7, 1243-51.
82. Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350: 586–597.
83. Schenk T, Enders M, Pollak S, Hahn R, Huzly D. High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy. J Clin Microbiol. 2009;47:106 –110;
84. Pankuweit S, Moll R, Baandrup U, et al. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Human Pathol. 2003;34:497–503.
85. Klein RM, Jiang H, Niederacher D, et al. Frequency and quantity of the parvovirus B19 genome in endomyocardial biopsies from patients with suspected myocarditis or idiopathic left ventricular dysfunction. Z Kardiol. 2004;93: 300–309.
86. Schowengerdt KO, Ni J, Denfield SW, Gajarski RJ, et al. Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation. 1997;96:3549 –3554.
87. Kuethe F, Lindner J, Matschke K, et al. Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clin Infect Dis. 2009;49:1660 –1666.
88. Tschope C., Bock C. T., Kasner M. et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005; 111: 7: 879—886.)
89. Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006;114:1581-90
90. Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med. 2010;362:1248-9
91. Pankuweit S, Lamparter S, Schoppet M, Maisch B. Parvovirus B19 genome in endomyocardial biopsy specimen. Circulation. 2004 Apr 13;109(14):e179.
92. Kühl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation Feb;111(7):887–93.
93. Donoso Mantke O, Meyer R, Prösch S, et al High prevalence of cardiotropic viruses in myocardial tissue from explanted hearts of heart transplant recipients and heart donors: a 3-year retrospective study from a German patients' pool. J Heart Lung Transplant 2005;24:
94. Wang X, Zhang G, Liu F, et al. Prevalence of human parvovirus B19 DNA in cardiac tissues of patients with congenital heart diseases indicated by nested PCR and in situ hybridization. J Clin Virol 2004;31:20-24
95 . Soderlund-Venermo M, Hokynar K, Nieminen J, et al. Persistence of human parvovirus B19 in human tissues. Pathol Biol (Paris) 2002; 50:307–16.;
96. Cassinotti P, Burtonboy G, Fopp M, Siegl G. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol 1997; 53: 229–32.
97. SoderlundM, von Essen R, Haapasaari J, KiistalaU, et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997; 349:1063–5.
98.Stewart GC, Lopez-Molina J, Gottumukkala RVet al. Myocardial parvovirus b19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure. Circ Heart Fail. 2011;4:71-8.
99. Lindner J, Noutsias M, Lassner D, et al. Adaptive immune responses against parvovirus B19 in patients with myocardial disease. J Clin Virol 2009; 44:27–32.25
100. Rohrer C, Gartner B, Sauerbrei A, et al. Seroprevalence of parvovirus B19 in the German population. Epidemiol Infect 2008; 136:1564–75.
101. Kawai C. Idiopathic cardiomyopathy: a study on the infectious-immune theory as a cause of the disease. Jpn Circ J. 1971;35:765–770.
102. Kawai C, Matsumori A, Kitaura Y, Takatsu T. Viruses and the heart: viral myocarditis and cardiomyopathy. Prog Cardiol. 1978;7:141–162.
103. Gauntt, C. and Huber, S. (2003) Coxsackievirus experimental heart diseases. Frontiers in Bioscience, 8, e23–35.
104. Takeda N. (2003) Cardiomyopathy: molecular and immunological aspects. Int. J. Mol. Med.
105. Ellis CR, Di Salvo T. Myocarditis: basic and clinical aspects. Cardiol. Rev 2007 15; 170-177.
106. Lee, GH., Badorff, C., & Knowlton, KU. (2000). Dissociation of sarcoglycans and the dystrophin carboxyl terminus from the sarcolemma in enteroviral cardiomyopathy. Circ Res 87:489–495.
107. Huber SA. Animal models: immunological aspects. In: Banatvla JE, ed. Viral Infections in the Heart. London, UK: Edward Arnold; 1993: 82–109.
108. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320–3.;
109. Bergelson JM, Mohanty JG, Crowell RL, et al. Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). J Virol 1995;69:1903–6.
110. Shafren DR, Bates RC, Agrez MV, et al. Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J Virol 1995;69:3873–7.
111. Coyne C, Bergelson J. CAR: a virus receptor within the tight junction. Adv Drug Deliv Rev 2005;57:869–82.
112. Shi Y, Chen C, Lisewski U, et al. Cardiac deletion of the coxsackievirus–adenovirus receptor abolishes coxsackievirus B3 infection and prevents myocarditis in vivo. J Mol Cell Cardiol 2009;53(14): 1219–26.).
113. Badorff C, Lee G H, Lamphear B J et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999; 5: 320–6.
114. Tomko R, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997;94:3352–6.
115. Shafren DR, Bates RC, Agrez MV, et al: Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J Virol 995;69:.
116. Wickham TJ, Filardo EJ, Cheresh DA, et al: Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 1994;127:257-264.).
117. Fechner H, Noutsias M, Tschoepe C, et al: Induction of coxsackievirus-adenovirus-receptor expression during myocardial tissue formation and remodeling: identification of a cell-to-cell contact-dependent regulatory mechanism. Circulation 2003;107: 876-882.
118. Kashimura T, Kodama M, Hotta Y, et al: Spatiotemporal changes of coxsackievirus and adenovirus receptor in rat hearts during postnatal development and in cultured cardiomyocytes of neonatal rat. Virchows Arch 2004;444:283-292.
119. Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med. 1994 Apr 28;330(17):1192-6.
120. Weigel-Kelley KA, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol. 2001;75(9):4110.
121. Weigel-Kelley KA, Yoder MC, Srivastava A. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood. 2003 Dec 1;102(12):3927-33.
122. Bültmann BD, Sotlar K, Klingel K. Parvovirus B19.N Engl J Med. 2004 May 6;350(19):2006-7.
123. Huber SA: Autoimmunity in coxsackievirus B3 induced myocarditis. Autoimmunity 2006;39:55-61.
124. Stella Yuen, Julie Smith, Laura Caruso, et al. The coxsackie–adenovirus receptor induces an inflammatory cardiomyopathy independent of viral infection, Journal of Molecular and Cellular Cardiology–840.).
125. Davies J. M. (1997) Molecular mimicry: can epitope mimicry induce autoimmune disease? Immunol. Cell Biol., 83: 93–102.
126. Lawson C. M. (2000) Evidence for mimicry by viral antigens in animal
models of autoimmune disease including myocarditis. Cell. Moll. Life, 57: 552–560.
127. Rose N. R. (2000) Viral damage or ≪molecular mimicry≫ — placing
the blame in myocarditis. Nat. Med., 6: 631–632.
128. Kytö V., Saraste A., Saukko P, et al. Apoptotic Cardiomyocite Death in Fatal Myocarditis. Am J Cardiol 2004; 94: 746-750.
129. Satoh M., Nakamura M., Akatsu T. et al. C-reactive protein co-expresses with tumor necrosis factor-alpha in the myocardium in human dilated сardiomyopathy. Eur J Heart Fail 2005; 7(5): 748-754.
130.Chang H. J., Chung J., Choi B. J. et al. The origin of proinflammatory cytokines in patients with idiopathic dilated cardiomyopathy. J Korean Med Sci. 2003; 8(6): 791-796.
131. Badorff C., Berkely N., Mehrotra S. et al. Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. J. Biol. Chem 2000; : .
132. Megeney L. A., Kablar B., Perry R. L. et al. Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc. Nad. Acad. Sci. USA 1999; 96: 220-225.
133.Fiers W., Beyaert R., Declercq W., Vandenabeele P. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 1999; 18: .
134.Kerr J. F., Saraste A., Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc. Res. 2000; 45: 528-537.
135. Yeh E. T.H. Autoimmunity and the Pathogenesis of Myocarditis. Circulation 1994; 89: .
136 .Pankuweit S, Portig I, Maisch B, et al: Pathophysiology of cardiac inflammation: Molecular mechanisms. Herz 2002; 27: 669-676.
137. Gauntt CJ, Arizpe HM, Higdon AL et al. Molecular mimicry, anti-coxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis. J Immunol 1995; 154: 2983–2995.
138.Huber SA, Pfaeffle B. Differential Th1 and Th2 cell responses in male and female BALB/ c mice infected with coxsackievirus group B type 3. J Virol 1994; 68: 5126–5132.
139.Noutsias M., Pauschinger M., Kuhl U. et al. (2002) Myocarditis and dilated cardiomyopathy. New methods in diagnosis and therapy. MMW Fortscher Med., 144: 36–40.
140.D'Ambrosio A, Patti G, Sinagra G, Di Lenarda A, Silvestri F, Di Sciascio G. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. // Heart 2001;85:499-504.
141. Why HJ, Meany BT, Richardson PJ, et al: Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 1994; 89: .
142.Dec G. W. Introduction to clinical myocarditis // Myocarditis: From Bench to Bedside / Cooper L. T. – Totowa, NJ: Humana Press Inc, 2003. – P. 257–281/
143. Cooper LT, Baughman KL, Feldman AM et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. J of the American College of Cardiology 2007;: 1914–1931.
144. Weinberg, M., Fell, E. H., and Lynfield, J. (1958). Diagnostic biopsy of the pericardium and myocardium.
Archives of Surgery, 76, 825
145. Sutton, D. C., and Sutton, G. C. (I960). Needle biopsy of the human ventricular myocardium: Review of 54 consecutive cases. American Heart Jrournal, 6o, 364
146. Soubihe, N. V. (I963). Punqao-biopsia do coraqao. Archivos del Instituto de Cardiologia de Mexico, 33, I32.
147. Konno, S., and Sakakibara, S. (I963). Endo-myocardial biopsy. Diseases of the Chest, 44, 345.
148. Bulloch RT, Murphy ML, Pearce MB. Intracardiac needle biopsy of the ventricular septum. Am J Cardiol 1965;16:227–33.
149. Caves PK, Stinson EB, Graham AF, Billingham ME, Grehl TM, Shumway NE. Percutaneous transvenous endomyocardial biopsy. JAMA 1973;225:288 –91.
150. Richardson PJ. King’s endomyocardial bioptome. Lancet 1974;1: 660 –1. Kawai C, Kitaura Y. New endomyocardial biopsy catheter for the left
ventricle. Am J Cardiol 1977;40:63–5.
151. Anderson JL, Marshall HW. The femoral venous approach to ndomyocardial biopsy: comparison with internal jugular and transarterial approaches. Am J Cardiol 1984;53:833–7
152. Edwards WD. Endomyocardial biopsy and cardiomyopathy. CVR & R 1990;11:26–43.
153. Osterhaus AD, Vos MC, Balk AH, et al. Transmission of hepatitis B virus among heart transplant recipients during endomyocardial biopsy procedures. J Heart Lung Transplant 1998;17:158–66/
154. Veinot JP. Diagnostic endomyocardial biopsy pathology—general biopsy considerations, and its use for myocarditis and cardiomyopathy: a review. Can J Cardiol 2002;18:55–65
155. Fowles RE, Mason JW. Endomyocardial biopsy. Ann Intern Med 1982; 97:885–94.
156. Holzmann M, Nicko A, Kuhl U, et plication rate of right ventricular endomyocardial biopsy via the femoral approach a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation 2008;118:1722–8.
157. Yilmaz A, Kindermann I, Kindermann M, et parative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 2010;122:900–9.
158. Miller LW, Labovitz AJ, McBride LA, Pennington DG, Kanter K. Echocardiography-guided endomyocardial biopsy: a 5-year experience. Circulation 1988;78:III99 –102.
159. Amitai ME, Schnittger I, Popp RL, Chow J, Brown P, Liang parison of three-dimensional echocardiography to two-dimensional echocardiography and fluoroscopy for monitoring of endomyocardial biopsy. Am J Cardiol 2007;99:864–6.
160. Mason JW. Techniques for right and left ventricular endomyocardial biopsy. Am J Cardiol 1978;41:887–92.
161. Lie JT. Myocarditis and endomyocardial biopsy in unexplained heart failure: a diagnosis in search of a disease. Ann Intern Med 1988; 109:5258.
162.Aretz HT, Billingham ME, Edwards WD et al: Myocarditis: A histopathologic definition and classification. Am J Cardiovasc Pathol 1:3, 1987.
163. Billingham ME. Acute myocarditis: is sampling error a contraindication
for diagnostic biopsies? J Am Coll Cardiol 1989;14:921–2.
164. Baandrup U, Florio RA, Olsen EG. Do endomyocardial biopsies represent the morphology of the rest of the myocardium? A quantitative light microscopic study of single v. multiple biopsies with the King's bioptome. Eur Heart J 1982;3:171–8.
165. Calabrese F, Thiene G. Myocarditis and inflammatory cardiomyopathy:
microbiological and molecular biological aspects. Cardiovasc Res 2003;60:11–25.
166. Mason JW, O'Connell JB, Herskowitz A et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333(5):269-275.
167. Shanes JG, Ghali J, Billingham ME et al. Interobserver variability in the pathologic interpretation of endomyocardial biopsy results. Circulation 1987; 75: 4
168. Magnani J. W., Dec G. W. Myocarditis: Current Trends in Diagnosis and Treatment. Circulation 2006;113;876—890.
169.Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis : implications for role of sampling error. Mayo Clin Proc. 1989; 64: .
170. Chow LH, Radio SJ, Sears TD, McManus BM. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol 1989; 14: 915–920.
171. Dulce M. C., Duerinckx A. J., Hartiala J., et al. MR imaging of the myocardium using nonionic contrast medium: signal-intensity changes in patients with subacute myocardial infarction //AJR Am J Roentgenol.- 1993.- Vol. 160. - P. 963970.
172. Abdel-Aty H, Simonetti O, Friedrich MG. T2-weighted cardiovascular magnetic resonance imaging. J Magn Reson Imaging 2007; 26:452–459.
173. Abdel-Aty H, Boye P, Zagrosek A et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 2005; 45:1815–1822.
174.Cocker MS, Abdel-Aty H, Strohm O, Friedrich MG. Age and gender effects on the extent of myocardial involvement in acute myocarditis: a cardiovascular magnetic resonance study. Heart 2009;95(23):1925-30.
175. Friedrich MG, Strohm O, Schulz-MengerJ et al.:Contrastmediaenhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 1998; 97:1802–1809.
176.Kim RJ, Judd RM, Chen EL et al. Relationship of elevated 23Na magnetic resonance image intensity to infarct size after acute reperfused myocardial infarction. Circulation 1999; 100: 185-192.
177.Thomson LE, Kim RJ, Judd RM. Magnetic resonance imaging for the assessment of myocardial viability. J Magn Reson Imaging 2004; 19: 771–788
178. Innoue S., Murakami Y., Ochiai K. et al. The contributory role of interstitial water in GD-DTPA-enhancedMRI in myocardial infarction // J. Magn. Reson. Imaging. 1999. No.9. Р.215-219.
179. Lima J. A., Judd R., Bazille A. et al. Regional heterogenity of human myocardial infarcts demonstrated by contrast-enhanced MRI: potential mechanisms // Circulation. 1995. V.92. P..
180. Gagliardi MG, Bevilacqua M, DiRenzi P et al. Usefulness of magnetic resonance imaging for diagnosis of acute myocarditis in infants and children, and comparison with endomyocardial biopsy. Am J Cardiol 1991; 68: 1089 –1091.
181.Gagliardi MG, Polletta B, DiRenzi P. MRI for the diagnosis and follow-up of myocarditis. Circulation 1999; 99: 458 –459.
182. Laissy JP, Messin B, Varenne O et al. MRI of acute myocarditis: a comprehensive approach based on various imaging sequences. Chest 2002; 122: 1638–1648.
183. Roditi GH, Hartnell GG, Cohen MC. MRI changes in myocarditis—evaluation with spin echo, cine MR angiography and contrast enhanced spin echo imaging. Clin Radiol 2000; 55: 752–758.
184.De Cobelli F, Pieroni M, Esposito A et al. Delayed gadoliniumenhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol 2006; 47: 1649 –1654.
185. Mahrholdt H, Wagner A, Deluigi CC et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006; 114: 1581-90.
186. Mahrholdt H, Goedecke C, Wagner A et al. Cardiovascular magnetic resonance assessment of humanmyocarditis: a comparison to histology and molecular pathology. Circulation 2004; 109:1250–1258
187. Abdel-Aty H, et al. Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease. Int J Cardiovasc Imaging 2008.
188. Rieker O, Mohrs O, Oberholzer K et al. Cardiac MRI in suspected myocarditis (in German). Rofo 2002; 174: 1530–1536.
189. Lieberman EB, Hutchins GM, Herskowitz A et al. Clinicopathologic description of myocarditis. J Am Coll Cardiol 1991; 18: 1617–1626.
190. Wagner A, Schulz-Menger J, Dietz R et al. Long-term follow-up of patients paragraph sign with acute myocarditis by magnetic resonance imaging. MAGMA 2003; 16(1): 17–20.
191. McCrohon JA, Moon JC, Prasad SK et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003; 108: 54–59.
192. Gutberlet M, Spors B, Thoma T et al. Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. Radiology 2008; 246: 401–409.
193. Assomull RG, Prasad SK, Lyne J et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006; 48:1977–1985.
194. Voigt A, Elgeti T, Durmus T et al. : Cardiac Magnetic Resonance Imaging in Dilated Cardiomyopathy in Adults—Towards Identification of Myocardial Inflammation. Eur Radiol 2011; 21(5): 925-935.
195.Röttgen R, Christiani R, Freyhardt P et al. Magnetic resonance imaging findings in acute myocarditis and correlation with immunohistological parameters. Eur Radiol 2011; 21(6): .
196. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (57):1–62.
197. Opasich C., Pinna G. D., Mazza A. et al. . Six-minute walking performance in patients with moderate in severe heart failure. Eur. Heart J.,2001;22:488-496.
198. Cerqueira MD, W. N., Dilsizian V, et al, Standardized myocardial segmentation andnomenclature for tomographic imaging of the heart: a statement for healthcare professionalsfrom the Cardiac Imaging Committee of the Council on Clinical Cardiology of the AmericanHeart Association // Circulation. – 2002. Vol. 105, № 4. – P. 539-542.
199. Caforio A, Pankuweit S, Arbustini E, et al.: Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.Eur Heart J 2013, 34(33):
200.Šramko M, Kubánek M, Tintěra J, et al. Utility of combination of cardiac magnetic resonance imaging and high-sensitivity cardiac troponin T assay in diagnosis of inflammatory cardiomyopathy. Am J Cardiol. 2013 Jan 15;111(2):258-64.
201. Bohl S, Wassmuth R, Abdel-Aty H, et al. Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease. Int J Cardiovasc Imaging 2008; 24:597–607.
202. Stensaeth K. Y., Hoffmann P., Fossum E., et al. Cardiac magnetic resonance visualizes acute and chronic myocardial injuries in myocarditis. Int J Cardiovasc Imaging 2011; 28:327–337.
203. Ingle L, Rigby AS, Nabb S et al. Clinical determinants of poor six-minute walk test performance in patients with left ventricular systolic dysfunction and no major structural heart disease.// Eur J Heart Fail. -2006.-Vol. 8(3).-P.321-5/
204. Kubánek M, Goode KM, Lánská V et al. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction.// Eur J Heart Fail. 2009 Jan 29.
205. O’Connor Ch., Fiuzat M., Lombardi C., et al. The Impact of Serial Troponin Release on Outcomes in Patients with Acute Heart Failure: Analysis from the PROTECT Pilot Study // Circulation: Heart Failure. — 2011. — 4. — 724732
206. Kociol D., Pang S., Gheorghiаade M., et al. Troponin Elevation in Heart Failure Prevalence, Mechanisms and Clinical Implications // J. Am. Coll. Cardiol. — 2010. — 56. — .
207. Halley C., Houghtaling P., Khalil M. Mortality rate in patients with diastolic dysfunction and normal systolic function // Arch. Intern. Med. — 2011. — 171. — .
208.Nagarajan V, Hernandez AV, Tang WH. Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. Heart. 2012; 98(24):1778-86
209. Lydell Carmen P, Emmanuelle Vermes, Helene C Childs, et al. Relationship of troponin T to cardiac MRI criteria for acute myocarditis. Journal of Cardiovascular Magnetic Resonance 2Suppl 1):P271. .
210. Wu E, Judd RM, Vargas JD, et al. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 2001; 357: 21–8.
|
Из за большого объема этот материал размещен на нескольких страницах:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
